Shadi Daoud, MD
Cardiovascular Disease · Las Vegas, NVNPI 1699739151
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Novartis at 49.3% of the total. Reporting peaked in 2019 at $12,708 and has fallen 85.7% since, to $1,820 in 2025.
Across 407 payments — averaging $65.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$13K
- AstraZeneca$5K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$934
- Amgen$611
- Abiomed$599
- plus $5K from 33 others
Across 1 payment — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
What the payments were for
- Consulting fees$3331%
- Speaking & faculty fees$15,43058%
- Food & beverage$10,93041%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 81 | $13,220 |
| AstraZeneca | 18 | $4,731 |
| Abbott | 21 | $1,877 |
| E.r. Squibb & Sons, L.L.C. | 51 | $934 |
| Amgen | 41 | $611 |
| Abiomed | 10 | $599 |
| Medtronic(2 entities) | 7 | $544 |
| Boehringer Ingelheim | 23 | $533 |
| Novo Nordisk | 25 | $511 |
| Pfizer | 24 | $426 |
| Philips North America LLC | 17 | $422 |
| Edwards Lifesciences | 7 | $304 |
| Boston Scientific | 6 | $265 |
| Merck | 12 | $244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $193 |
| Johnson & Johnson | 11 | $167 |
| Biosense Webster, Inc. | 4 | $163 |
| Bridgebio Pharma, Inc. | 4 | $111 |
| Itamar Medical Inc | 2 | $108 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $97 |
| Alnylam Pharmaceuticals Inc. | 3 | $88 |
| Lantheus Medical Imaging, Inc. | 4 | $83 |
| Kowa Pharmaceuticals America, Inc. | 3 | $70 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $55 |
| Bayer | 3 | $54 |
| Lexicon Pharmaceuticals, Inc. | 2 | $53 |
| Heartflow, Inc. | 2 | $51 |
| Cvrx, Inc. | 2 | $51 |
| Atricure, Inc. | 2 | $45 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Teleflex LLC | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Shockwave Medical, Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$11,840
- FARXIGA$4,425
- CardioMEMS HF System$513
- Impella$397
- Confirm Rx$258
- HeartMate 3 Left Ventricular Dev$175
- Ensite Cardiac Mapping System$169
- AVEIR$164
- Edwards SAPIEN 3 Transcatheter Heart Valve$148
- Advisor Catheter$145
- LEQVIO$118
- Watchman$100
How this compares
$26,823 in reported general payments places this provider in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 14 | $314,884 |
| EntrestoSacubitril/Valsartan | 197 | $210,379 |
| EliquisApixaban | 163 | $209,088 |
| JardianceEmpagliflozin | 183 | $175,891 |
| XareltoRivaroxaban | 81 | $90,609 |
| FarxigaDapagliflozin Propanediol | 119 | $81,796 |
| OzempicSemaglutide | 33 | $46,083 |
| VascepaIcosapent Ethyl | 15 | $9,603 |
| Midodrine Hcl | 45 | $4,107 |
| Tacrolimus | 21 | $4,097 |
| Metoprolol Succinate | 272 | $3,655 |
| Torsemide | 124 | $2,014 |
| Atorvastatin Calcium | 259 | $1,891 |
| Carvedilol | 168 | $1,679 |
| Flecainide Acetate | 16 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $426 | $523,972177 claims |
| NovartisEntresto | $13,220 | $210,379197 claims |
| Boehringer IngelheimJardiance | $533 | $175,891183 claims |
| Johnson & JohnsonXarelto | $167 | $90,60981 claims |
| AstraZenecaFarxiga | $4,731 | $81,796119 claims |
| Novo NordiskOzempic | $511 | $46,08333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.